Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai Patents (Class 514/183)
  • Publication number: 20130203724
    Abstract: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog.
    Type: Application
    Filed: August 20, 2012
    Publication date: August 8, 2013
    Applicant: Infinity Discovery, Inc.
    Inventors: Julian Adams, Yun Gao, Asimina T. Georges Evangelinos, Louis Grenier, Roger H. Pak, James R. Porter, James L. Wright
  • Patent number: 8501760
    Abstract: A pharmaceutical composition, especially capsules, comprising granules containing nilotinib or a salt thereof with at least one pharmaceutically acceptable excipient. The granules may be produced by a wet granulation process.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: August 6, 2013
    Assignee: Novartis AG
    Inventor: Nathalie Bruneau
  • Patent number: 8501724
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: August 6, 2013
    Assignee: Pharmacyclics, Inc.
    Inventors: Wei Chen, David J. Loury
  • Patent number: 8501722
    Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides compounds as therapeutic agents against bacterial infections.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: August 6, 2013
    Assignee: The Regents of the University of Michigan
    Inventors: David Ginsburg, Hongmin Sun, Scott Larsen, Bryan Yestrepsky
  • Patent number: 8501723
    Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: August 6, 2013
    Assignee: UCB Pharma GmbH
    Inventors: Hans-Jürgen Mika, Christoph Arth, Michael Komenda, Fatima Bicane, Kerstin Paulus, Meike Irngartinger, Hans Lindner
  • Publication number: 20130195922
    Abstract: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
    Type: Application
    Filed: August 1, 2012
    Publication date: August 1, 2013
    Applicant: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Tapas De
  • Patent number: 8497245
    Abstract: The invention provides methods of making and using compounds of the formula: or a pharmaceutically acceptable salt thereof; wherein n is an integer between 1 and 2 inclusively; m is an integer between 0 and 2 inclusively; X is selected from the group consisting of CH or N; R1 is selected from the group consisting of —CH2NH2, and R2 is selected from the group consisting of —H, —OH, —NH2 and acetyl; R3 is selected from the group consisting of —H, benzyloxycarbonyl and benzylsulfonyl; and R4 is selected from the group consisting of —OH, wherein p is an integer between 0 and 2 inclusively, Y is selected from the group consisting of —O—, —S—, —S(?O)—, —SO2—, methylene, —CH(OH)—, —CH(NH2)—, —CH(CH2—OH)—, —CH(CH2—NH2)— or —N(R6)—, R5 is selected from the group consisting of —H or a simple (C1-C3) alkyl and R6 is selected from the group consisting of —H, a simple (C1-C3) alkyl or a simple (C1-C3) acyl.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: July 30, 2013
    Assignee: The Medicines Company (Leipzig) GmbH
    Inventors: Peter Herold, Stjepan Jelakovic, Mohammed Daghish, Claudia Reichelt, Alexander Schulze, Andrea Schweinitz, Friedrich-Alexander Ludwig, Adel Rafai Far, Ting Kang
  • Patent number: 8497259
    Abstract: There is proposed a method for using a preparation for lowering the cholesterol level of a patient. In preferred embodiments, the preparation essentially consists of an active substance being an aqueous solution of formaldehyde with a concentration of 36.5-40%, the active substance constitutes 2-6 weight units, and an additive being an isotonic solution of sodium chloride with a concentration of 0.85-0.95%, the additive constitutes from 998 to 994 weight units accordingly, to make the total of 1000 weight units. The method includes administering the preparation to the patient in the form of intramuscular injections with a predetermined dose at a predetermined time interval, thereby lowering the cholesterol level of the patient. It is preferable to choose the predetermined time interval from the group consisting of 7, 21, 30, and 60 days. It is also preferable to choose the predetermined dose in the amount of 5 mL.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: July 30, 2013
    Inventors: Vladislav Nikolaevich Laskavy, Aleksandr Nikolaevich Shokhin, Sergei Ivanovich Ivanenko
  • Patent number: 8492420
    Abstract: The invention relates to the use of purine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells, said derivatives being of formula (I): where R2, R6 and R9, independently=halogen, a R—NH—, R—NH—NH—, NH2—R?—NH or R—NH—R?—NH— group, where R=straight or branched chain saturated or unsaturated alkyl, aryl, cycloalkyl, or heterocyclyl group, R?=straight or branched chain, saturated or unsaturated alkylene, arylene or cycloalkylene, R and R? each include 1 to 8 carbon atoms optionally substituted with one or more —OH, halogen, amino or alkyl groups, R2 furthermore may be a heterocycle optionally with a straight or branched chain saturated or unsaturated alkyl, aryl or cycloaryl or a heterocycle optionally substituted by one or more —OH, halogen, amino or alkyl groups, R9 furthermore may be a straight or branched chain saturated or unsaturated alkyl, aryl or cycloalkyl and R2 and R9 furthermore may be hydrogen with the exception
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: July 23, 2013
    Assignees: Centre National de la Recherche Scientifique-CNRS, Universite de Poitiers
    Inventors: Frédéric Becq, Laurent Meijer
  • Patent number: 8492370
    Abstract: The present invention relates to ansamycin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases or a prophylactic pretreatment for cancer. The present invention also provides methods for the production of these compounds and their use in medicine.
    Type: Grant
    Filed: November 9, 2007
    Date of Patent: July 23, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventor: Christine Martin
  • Patent number: 8492386
    Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: July 23, 2013
    Assignee: AbbVie Inc.
    Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Thomas J. Podsadecki, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein
  • Patent number: 8486928
    Abstract: The present invention relates to compounds which are effective as catalysts for dismutating superoxide and, more particularly, the manganese or iron complexes of substituted, unsaturated heterocyclic 16-membered macrocyclic complexes that catalytically dismutate superoxide. It also relates to methods of using these complexes to reduce the concentration or the effects of superoxide, pharmaceutical compositions comprising these compounds or their metal complexes, and methods of treating conditions associated with excessive superoxide activity.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: July 16, 2013
    Assignee: Galera Therapeutics
    Inventor: Dennis P. Riley
  • Patent number: 8486927
    Abstract: The invention is directed to novel crystalline forms of lamotrigine. These novel crystalline forms of lamotrigine have improved dissolution and in-vivo absorption profile, as compared to pure lamotrigine. These novel crystalline forms of lamotrigine provide a substantial increase in the blood concentration of lamotrigine, as compared to pure lamotrigine when administered to a subject. These novel crystalline forms of lamotrigine also provide a slower, steady build up of lamotrigine blood concentration suitable for sustained release of lamotrigine in-vivo, as compared to pure lamotrigine.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: July 16, 2013
    Assignee: Thar Pharmaceuticals
    Inventors: Mazen Hanna, Ning Shan, Miranda L. Cheney
  • Patent number: 8486926
    Abstract: The invention relates to solid state forms of androst-5-ene-3?,7?,16?,17?-triol, formulations containing or prepared from such solid state forms and use of such materials for modulating acute and chronic non-productive inflammation. The formulations can be used to prevent, treat or slow the progression of conditions related to autoimmunity such as arthritis, multiple sclerosis, ulcerative colitis or Type 1 diabetes. The formulations can also be used to prevent, treat or slow the progression of conditions related to metabolic disorders such as Type 2 diabetes.
    Type: Grant
    Filed: November 17, 2008
    Date of Patent: July 16, 2013
    Assignee: Harbor Therapeutics, Inc.
    Inventors: James Frincke, Marvin Lewbart, Christopher Reading
  • Patent number: 8481518
    Abstract: The present invention relates to a method for treating bladder disease, including urinary incontinence, which involves intravesical administration of quaternary antimuscarinic compounds having longer duration of effect and fewer side effects than standard treatments.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: July 9, 2013
    Assignee: University of Rochester
    Inventor: Ronald W. Wood
  • Patent number: 8481083
    Abstract: Compositions are provided that are useful for the preparation of a medicament. The compositions comprise granules having a layer of sodium picosulphate coated on potassium bicarbonate. Additional granules having a layer of magnesium oxide coated on a core of citric acid are also provided. The two types of granules may be combined to obtain mixtures (preferably homogeneous or substantially homogeneous mixtures) of the two types of granules, which are useful, e.g., as pharmaceutical compositions.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: July 9, 2013
    Assignee: Ferring International Center S.A.
    Inventors: Haijun Xu, Tiejun Diao
  • Patent number: 8481520
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: July 9, 2013
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: Michael Eissenstat, Dehui Duan
  • Patent number: 8481521
    Abstract: The present disclosure provides methods for the treatment of cell proliferative disorders by administration of a Syk kinase or Syk/Flt-3 kinase inhibitor. Cell proliferative disorders treatable by the methods include, hematopoietic neoplasms and virally associated tumors. The compounds are also directed to therapeutic or prophylactic inhibition of tumor metastasis.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: July 9, 2013
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Donald G. Payan, Elliot B. Grossbard, Somasekhar Bhamidipati, Rajinder Singh
  • Patent number: 8481519
    Abstract: A method for isolating atraric acid from biological material, atraric acid derivatives, the chemical synthesis thereof, and the use of atraric acid and the derivatives thereof for treating or producing a medicament for treating benign prostate hyperplasia, prostate carcinoma or spinobulbar muscular atrophy is provided. In addition, a basic substance for the development of other agents used for treating benign prostate hyperplasia, prostate carcinoma, or spinobulbar muscular atrophy is provided.
    Type: Grant
    Filed: January 28, 2006
    Date of Patent: July 9, 2013
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Hans-Rainer Hoffmann, Rudolf Matusch, Aria Baniahmad
  • Publication number: 20130172319
    Abstract: The invention relates to the generation of a library of compounds enriched in agonist and antagonists for members of the G-protein coupled class of receptors (GPCRs). The library contains compounds of general formula (II) wherein: y is any integer from 1 to 8; X is —CO—R1 or —SO2—R1; each R1 is independently selected from an alkyl, haloalkyl, alkenyl, alkynyl, alkylaminoalkyl, alkylaminodialkyl, or charged alkylaminotrialkyl, radical of 1 to 20 carbon atoms; or each R1 is independently selected from oxyalkyl, aminoalkyl, aminodialkyl, or charged aminotrialkyl radical; and wherein the R1 radical has a “key” carbon next to the carbonyl of the carbon amide or the sulfonyl group of the sulfonamide which is di-substituted with the same or different groups selected from: alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl and alkylamino radicals.
    Type: Application
    Filed: February 26, 2013
    Publication date: July 4, 2013
    Applicants: CAMBRIDGE ENTERPRISE LIMITED
    Inventors: Cambridge Enterprise Limited, David J. Grainger, David John Fox
  • Patent number: 8476192
    Abstract: An aqueous seed treatment insecticidal and/or nematicidal composition in the form of a suspension comprising (A) at least one insecticide and/or nematicide in an amount of at least 3 weight %, based on the total weight of the composition, and (B) at least two surface active compounds, wherein (i) at least one is an anionic phosphate type compound, and (ii) at least one is a non-ionic alkoxylated phenol. Such compositions demonstrate improved dust-off performance when applied to plant propagation material, such as seeds.
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: July 2, 2013
    Assignee: Syngenta Crop Protection LLC
    Inventors: Lear Michael Haulsee, Humberto B. Lopez
  • Patent number: 8476255
    Abstract: Provided herein are novel, stilbene like compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, metabolites, prodrugs, solvates, pharmaceutically acceptable salts and compositions thereof. These compounds can inhibit HDACs and are useful as a therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, autoimmune diseases, skin diseases, infections, inflammation, etc.
    Type: Grant
    Filed: October 8, 2008
    Date of Patent: July 2, 2013
    Assignee: Orchid Chemicals & Pharmaceuticals Limited
    Inventors: Sridharan Rajagopal, Virendra Kachhadia, Thanasekaran Ponpandian, Abdul Raheem Keeri, Umamaheswari Mani, Suresh Rathinasamy, Praveen Rajendran, Kamaraj Mani, Balaji Ramachandran, Punthalir Narayanaswamy, Sriram Rajagopal
  • Patent number: 8476256
    Abstract: Novel diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: July 2, 2013
    Assignee: Joyant Pharmaceuticals, Inc.
    Inventors: Gunnar James Hanson, Ming Zhou, Qi Wei, Charles Caldwell
  • Patent number: 8466159
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: June 18, 2013
    Assignee: AbbVie Inc.
    Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Thomas J. Podsadecki, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein
  • Patent number: 8466141
    Abstract: Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: June 18, 2013
    Assignees: MD Bioalpha Co., Ltd., KT & G Co., Ltd.
    Inventors: Sang-Ku Yoo, Myunggyu Park, In Geun Jo, Taehwan Kwak
  • Patent number: 8466140
    Abstract: Described are mitochondria-targeted anti-tumor agents, and methods of making and using the same for the treatment of disorders associated with unwanted cell proliferation.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: June 18, 2013
    Assignee: University of Massachusetts
    Inventors: Dario C. Altieri, Byoung Heon Kang
  • Publication number: 20130150350
    Abstract: Compounds of formula (I) wherein m, R1, R2, R3, X and Y are defined herein, are useful as inhibitors of HIV replication.
    Type: Application
    Filed: February 9, 2011
    Publication date: June 13, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Bruno Simoneau, Patrick Deroy, Lee Fader, Anne-Marie Faucher, Alexander Gagnon, Chantal Grand-Maitre, Stephen Kawai, Serge Landry, Jean-Francois Mercier, Jean Rancourt
  • Patent number: 8461141
    Abstract: It is intended to provide a highly safe preventive or therapeutic drug for Alzheimer-type dementia which can replace the conventional therapies currently used for Alzheimer-type dementia or which can be used together with the conventional therapy to realize high therapeutic effects, characterized in that a ?-3 polyunsaturated fatty acid and thyroid hormone are used in combination.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: June 11, 2013
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kiyoshi Hashizume
  • Publication number: 20130143855
    Abstract: A method of alleviating end-stage renal disease (ESRD), comprising administering an effective amount of a gel-danamycin derivative.
    Type: Application
    Filed: May 25, 2011
    Publication date: June 6, 2013
    Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Bin-Xian Zhang
  • Patent number: 8455472
    Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: June 4, 2013
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Patent number: 8455470
    Abstract: The present invention relates to a pharmaceutical composition useful for treating or preventing inflammatory disease and cell damage, and a method for treating or preventing inflammatory disease and cell damage. The present invention uses the 2-hydroxybenzoic acid derivative represented by the specific chemical formula or its pharmaceutically acceptable salt. The compound of the present invention is useful for treating or preventing cell damage and inflammatory disease including gastritis, gastric ulcer, pancreatitis, colitis, arthritis, diabetes, arteriosclerosis, nephritis, hepatitis, Alzheimer's disease, Parkinson's disease and Lou Gehrig's disease.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: June 4, 2013
    Assignee: Neurotech Pharmaceuticals Co., Ltd
    Inventors: Byoung-Joo Gwag, Sung-Ig Cho, Jae-Young Cho, Young-Ae Lee, Han-Yeol Byun, Doo-Soon Lim, Ki-Baik Hahm, Young-Bae Kwon, Jin-Hwan Lee, Bok-Seon Yoon, Chun-San An, Keun-Sil Ryu
  • Patent number: 8455440
    Abstract: The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: June 4, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Stanley J. Hollenbach, Patrick Andre
  • Patent number: 8455471
    Abstract: Compositions containing at least one Chk1 inhibitor and at lease one cyclodextrin are disclosed. Also disclosed are methods of treating a cancer or potentiating a cancer treatment with a composition comprising at least one Chk1 inhibitor and at least one cyclodextrin.
    Type: Grant
    Filed: October 2, 2007
    Date of Patent: June 4, 2013
    Assignee: ICOS Corporation
    Inventors: Wendy A. Wisdom, Anita A. Colvin, Sandy Koppenol
  • Patent number: 8455473
    Abstract: Composition and method for irrigating a prepared dental root canal. The composition is an aqueous composition of ethylenediamine tetraacetic acid, chlorhexidine or orally acceptable addition salt, and N-cetyl-N,N,N-trimethylammonium bromide, and is effective for simultaneous smear layer removal and disinfection.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: June 4, 2013
    Assignee: The University of British Columbia
    Inventor: Marcus Haapasalo
  • Patent number: 8455496
    Abstract: The present invention provides compounds of Formula (I) that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: June 4, 2013
    Assignee: Pfizer Inc.
    Inventors: Jeffrey Allen Pfefferkorn, Anthony Lai Ling
  • Patent number: 8450302
    Abstract: The present invention relates to the use of masitinib or a pharmaceutically acceptable salt thereof, and in particular of masitinib mesylate, for the preparation of a medicament for the treatment of GIST, to the use of this therapy for the treatment of GIST, and a method of treating mammals, including humans, suffering from GIST by administering to said mammal in need of such treatment an effective dose of masitinib, and in particular masitinib mesylate.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: May 28, 2013
    Assignee: AB Science
    Inventors: Marco Ciufolini, Camille Wermuth, Bruno Giethlen, Alain Moussy, Jean-Pierre Kinet
  • Patent number: 8450338
    Abstract: Compositions are provided that are useful for the preparation of a medicament. The compositions comprise granules having a layer of sodium picosulphate coated on potassium bicarbonate. Additional granules having a layer of magnesium oxide coated on a core of citric acid are also provided. The two types of granules may be combined to obtain mixtures (preferably homogeneous or substantially homogeneous mixtures) of the two types of granules, which are useful, e.g., as pharmaceutical compositions.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: May 28, 2013
    Assignee: Ferring International Center S.A.
    Inventors: Haijun Xu, Tiejun Diao
  • Patent number: 8450301
    Abstract: The invention relates to the use of piperazine compounds of formula (I) or the agriculturally useful salts of piperazine compounds of formula (I) as herbicides, the variables in formula (I) being defined as cited in the claims and the description.
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: May 28, 2013
    Assignee: BASF SE
    Inventors: Eike Hupe, Cyrill Zagar, Matthias Witschel, Toralf Kühn, William Karl Moberg, Liliana Parra Rapado, Frank Stelzer, Andrea Vescovi, Michael Puhl, Robert Reinhard, Bernd Sievernich, Klaus Groβmann, Thomas Ehrhardt, Michael Rack
  • Patent number: 8450479
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (collectively referred to herein as 3TM compounds). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: May 28, 2013
    Assignee: Pharminox Limited
    Inventors: Malcolm Francis Graham Stevens, David Cousin, Sharon Jennings, Andrew James McCarroll, John Gareth Williams, Marc Geoffery Hummersone, Jihong Zhang
  • Publication number: 20130129814
    Abstract: The present invention relates to the regional delivery of therapeutic agents for the treatment of vascular diseases wherein regional delivery refers to delivery of a therapeutically effective amount of the therapeutic agent to an area of the vessel that includes not only afflicted tissue but non-afflicted tissue at the periphery of the afflicted tissue as well.
    Type: Application
    Filed: December 21, 2012
    Publication date: May 23, 2013
    Applicant: ABBOTT CARDIOVASCULAR SYSTEMS INC.
    Inventor: ABBOTT CARDIOVASCULAR SYSTEMS INC.
  • Patent number: 8445722
    Abstract: The present invention relates to a method for screening an anticancer compound and an anticancer compound screened using the method, and more particularly, to a method for screening an anticancer compound, the method comprising: culturing cancer cells expressing the oncogenic protein transmembrane 4 L6 family member 5 (TM4SF5), expressed as the polypeptide of SEQ ID NO: 2, treating the cancer cells with an anticancer candidate, and determining that the anticancer candidate is an anticancer substance when the candidate exhibits antagonistic activity against tumor formation and metastasis based on several events through the molecular mechanism of TM4SF5. The present invention also relates to chalcone compounds screened to have anticancer activity using the method, and an anticancer composition comprising the compound as an effective ingredient.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: May 21, 2013
    Assignees: Industry-Academic Cooperation Foundation Gyeongsang National University, Seoul National University Industry Foundation
    Inventors: Ki Hun Park, Jung Weon Lee, Young Bae Ryu, Hyung Won Ryu, Sin-Ae Lee
  • Patent number: 8445474
    Abstract: Compositions of predetermined amounts of R(+) pramipexole and S(?) pramipexole and methods of using the same, including for the treatment and prevention of Parkinson's disease, are provided.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: May 21, 2013
    Assignee: Knopp Neurosciences, Inc.
    Inventors: Michael E. Bozik, Thomas Petzinger, Jr., Valentin Gribkoff
  • Patent number: 8445473
    Abstract: The invention relates to heteroaryl-substituted bicyclic mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: May 21, 2013
    Assignee: The Regents of the University of Michigan
    Inventors: Shaomeng Wang, Haiying Sun, Zaneta Nikolovska-Coleska
  • Patent number: 8440650
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: May 14, 2013
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Breackman, Paresh Soni
  • Patent number: 8440649
    Abstract: Treatment of coronavirus infection with phenanthroindolizidine analogues.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: May 14, 2013
    Assignee: National Health Research Institutes
    Inventors: Shiow-Ju Lee, Cheng-Wei Yang, Yue-Zhi Lee
  • Patent number: 8440675
    Abstract: To provide a radiation therapy potentiator, which, when employed in combination with cancer radiation therapy, can reduce radiation dose and can mitigate adverse effects. The invention provides a radiation therapy potentiator containing, as an effective ingredient, a uracil derivative represented by formula (1) (wherein R1 represents a halogen atom or a cyano group; and R2 represents a 4- to 8-membered heterocyclic group having 1 to 3 nitrogen atoms and optionally having as a substituent a lower alkyl group, an imino group, a hydroxyl group, a hydroxymethyl group, a methanesulfonyloxy group, or an amino group; an amidinothio group in which a hydrogen atom attached to a nitrogen atom may be substituted by a lower alkyl group; a guanidino group in which a hydrogen atom attached to a nitrogen atom may be substituted by a lower alkyl group or a cyano group; a lower alkylamidino group; or a 1-pyrrolidinylmethyl group) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: May 14, 2013
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventor: Masakazu Fukushima
  • Patent number: 8440648
    Abstract: The present invention provides for compositions, kits and methods for treatment of intraepithelial neoplasia, where the compositions include catecholic butanes, which include NDGA derivatives.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: May 14, 2013
    Assignees: Erimos Pharmaceuticals LLC, University of Maryland, Baltimore, Johns Hopkins University
    Inventors: Neil Frazer, Jonathan Heller, Rocio Lopez, Melissa Rhodes, Ru Chih C. Huang, Richard Dalby, Niharika Khanna
  • Patent number: 8435976
    Abstract: The invention relates to compounds of formula (I) which are useful as kinase inhibitors, more specifically useful as PIM kinase inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same, either alone or in combination, to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: May 7, 2013
    Assignee: F. Hoffmann-La Roche
    Inventors: Xiaojing Wang, Allen J. Ebens, Jr.
  • Patent number: 8436031
    Abstract: Substituted benzoimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compounds, as well as pharmaceutical preparations thereof, in, e.g., reducing antibiotic resistance and inhibiting biofilms.
    Type: Grant
    Filed: August 3, 2009
    Date of Patent: May 7, 2013
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventor: Oak K. Kim
  • Patent number: 8435497
    Abstract: The invention relates to pharmaceutical compositions containing combinations of formoterol and ciclesonide and the use of such pharmaceutical compositions in medicine, in particular, the prophylaxis and treatment of respiratory disease.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: May 7, 2013
    Assignee: Takeda GmbH
    Inventors: Klaus Dietzel, Helgert Mueller